NCT07093476View on ClinicalTrials.gov

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

PHASE3RecruitingINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
T2DMDiabete Type 2DM
Interventions
DRUG

Metformin

tablets, QD, oral administration

DRUG

Alogliptin

tablets, QD, oral administration

DRUG

empagliflozin

tablets, QD, oral administration

Trial Locations (1)

Unknown

RECRUITING

Celltrion, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT07093476 - Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | Biotech Hunter | Biotech Hunter